HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2024 European Hematology Association (EHA) Congress, taking place June 13-16, 2024 in Madrid, Spain. Jorge Cortes, M.D., Director of the Georgia Cancer Center, will present interim results from the Company's ...

HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL. Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, will p ...

Bio-Path Holdings Inc. (NASDAQ:BPTH) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - Chief Executive Officer and Chief Financial Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol Name of each exchange on which registered FORM 8-K Date of report (Date of earliest event reported): May 15, 2024 (Exact name of registrant as specified in its charter) (832) 742-1357 (Registrant's Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ...

Delaware 87-0652870 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Or Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36333 (Exact name of registrant as specified in its charter) Securiti ...

HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) (the "Company" or "Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and concurrent pri ...

Bio-Path Holdings, Inc. (BPTH) announced that it has completed the second dose cohort in the dose-escalation portion of an early-stage study evaluating its investigational candidate, BP1002, for the treatment of refractory/relapsed (R/R) acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.The novel AML therapy, BP1002, is being developed by leveraging Bio-Path’s proprietary DNAbilize antisense RNAi nanoparticle technology. Per the company, BP1002 targets the Bcl-2 protein, which i ...

HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) (the "Company" or "Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offerin ...

Bio-Path (NASDAQ:BPTH) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002.This clinical trial is focusing on the use of BP1002 as a treatment for refractory/relapsed acute myeloid leukemia (AML). It’s focusing on patients with AML and patients who are venetoclax resistant.Bio-Path is currently testing the dose escalation portion of its Phase 1/1b study. The company notes that it has successfully completed its second dose cohort in thi ...

HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patient ...